Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
doi:10.1378/chest.06-2179
(Chest. 2007; 131:1557-1566)
© 2007 American College of Chest Physicians
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yanbaeva, D. G.
Right arrow Articles by Wouters, E. F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanbaeva, D. G.
Right arrow Articles by Wouters, E. F. M.

Systemic Effects of Smoking*

Dilyara G. Yanbaeva, PhD; Mieke A. Dentener, PhD; Eva C. Creutzberg, PhD; Geertjan Wesseling, MD, PhD and Emiel F. M. Wouters, MD, PhD, FCCP

* From the Department of Respiratory Medicine (Drs. Yanbaeva, Dentener, Wesseling, and Wouters), University Hospital Maastricht/Maastricht University, Maastricht, the Netherlands; and CIRO Horn (Dr. Creutzberg), Haelen, the Netherlands.

Correspondence to: Emiel F. M. Wouters, MD, PhD, FCCP, Department of Respiratory Medicine, University Hospital Maastricht/Maastricht University, PO Box 580, 6202 AZ Maastricht, the Netherlands; e-mail: e.wouters{at}lung.azm.nl

Abstract

Smoking is one of the major lifestyle factors influencing the health of human beings. Life-long cigarette smokers have a higher prevalence of common diseases such as atherosclerosis and COPD with significant systemic impact. The present review evaluates current knowledge concerning possible pathways through which cigarette smoking can affect human health, with special focus on extrapulmonary effects. Long-term smoke exposure can result in systemic oxidants-antioxidants imbalance as reflected by increased products of lipid peroxidation and depleted levels of antioxidants like vitamins A and C in plasma of smokers. A low-grade systemic inflammatory response is evident in smokers as confirmed by numerous population-based studies: elevated levels of C-reactive protein (CRP), fibrinogen, and interleukin-6, as well as increased counts of WBC have been reported. Furthermore, rheologic, coagulation and endothelial function markers like hematocrit, blood and/or plasma viscosity, fibrin d-dimer, circulating adhesion molecules (intracellular adhesion molecule-1, selectins), tissue plasminogen activator antigen, and plasminogen activator inhibitor type I are altered in chronic cigarette smokers. Although most of smoking-induced changes are reversible after quitting, some inflammatory mediators like CRP are still significantly raised in ex-smokers up to 10 to 20 years after quitting, suggesting ongoing low-grade inflammatory response persisting in former smokers. New longitudinal epidemiologic and genetic studies are required to evaluate the role of smoking itself and possible gene/environment interplay in initiation and development of smoking-induced common diseases affecting humans.

Key Words: endothelial dysfunction • hemostasis • smoking • systemic inflammation • systemic oxidative stress

Tobacco smoking is one of the most potent and prevalent addictive habits, influencing behavior of human beings for > 4 centuries. Smoking is now increasing rapidly throughout the developing world and is one of the biggest threats to current and future world health.1 Furthermore, while the prevalence of tobacco use has declined among men in some high-income countries, it is still increasing among young people and women.2 Cigarette smoking is the most common type of tobacco use. In average, to date 47.5% of men and 10.3% of women are current smokers. Tobacco continues to be the second major cause of death in the world. By 2030, if current trends continue, smoking will kill > 9 million people annually.3

Tobacco smoking affects multiple organ systems resulting in numerous so-called tobacco-related diseases. The well-known health risks in tobacco smoking pertain to diseases of the respiratory tract such as COPD and cancer, particularly lung cancer and cancers of the larynx and tongue.45

While the adverse effects of cigarette smoke on lung health are well established, it is becoming more evident that smoke has an important extrapulmonary toxicity. Injury in the lung, primary target of inhaled smoke, can be explained by the direct chemical exposure to cigarette smoke, but effects causing chronic diseases in other organ systems are likely to be the result of indirect consequences of the exposure. However, despite the overwhelming amount of studies demonstrating the relationship of smoking with numerous widespread "systemic" diseases such as atherosclerosis and COPD, the precise mechanisms how smoke potentiates its systemic effects need to be clarified. In a article by van der Vaart et al,6 the local and systemic effects of acute smoke exposure on oxidative stress and inflammatory mediators were reviewed. In the present article, we aim to review systemic effects of long-term smoking exposure in humans. In particular, traditional markers of generalized response to smoking such as systemic oxidative stress and systemic inflammation are reviewed. In addition, in view of findings suggesting the relationship between some of these markers and atherosclerosis, aspects of hemostatic and coagulation systems are discussed in relation to tobacco smoking.

Systemic Oxidative Stress in Smokers

Cigarette smoke contains approximately 1017 oxidant molecules per puff.7 This oxidative stress can be registered in several different ways, either by direct measurements of the oxidative burden (reactive oxygen species [ROS] production by peripheral blood cells) or by the effects of oxidative stress on target molecules (lipid peroxidation products and oxidized proteins), or as the responses to the oxidative stress (antioxidant capacity of plasma)8 [Table 1 ].


View this table:
[in this window]
[in a new window]

  		Table 1. Markers of Increased Oxidative Stress in Smokers

 
Only a few studies91011 have used ROS production by blood cells extracted from the circulation of smokers. Perhaps more important than the presence of oxidative stress are the effects of this oxidative stress on a variety of vital target molecules. Numerous markers for oxidative damage have been proposed, including oxidation and nitration of proteins. For example, nitration of tyrosine residues of proteins leads to the production of 3-nitrotyrosine, which may be considered as a marker of nitric oxide (NO)-dependent oxidative damage. Indeed, NO-mediated and peroxynitrite-mediated formation of 3-nitrotyrosine is elevated in plasma and platelets of chronic smokers.1213 Furthermore, Pignatelli and coworkers14 reported significantly higher levels of nitrated and oxidized fibrinogen, transferrin, plasminogen, and ceruloplasmin in smokers than in nonsmokers.

Free radicals from cigarette smoke also cause peroxidation of the polyunsaturated fatty acids of cell membranes that amplify oxidative stress during smoking. The F2-isoprostanes, prostaglandin-like compounds, are products of free radical-catalyzed lipid peroxidation of arachidonic acid. Several studies151617 have reported an increased level of isoprostane 8-iso-prostaglandin F2 (PGF2){alpha} formation in smokers. It has been found that urinary 8-epi-PGF2{alpha} excretion was significantly increased in long-term current and former smokers compared with the age- and sex-matched nonsmoking control subjects.17 In addition, a dose-response relationship was observed between the number of cigarettes smoked and both urinary cotinine and urinary 8-epi-PGF2{alpha}.16 The biological role of isoprostanes is not clear yet. It has been shown that F2 isoprostane levels are significantly increased in atherosclerotic plaques compared with normal vascular tissue, suggesting that these compounds may play a role in the pathogenesis of the disease.18 The observation of elevated levels urinary 8-iso-PGF2{alpha} in patients with coronary heart disease strengthens this hypothesis.19

Increased levels of malondialdehyde, which are degradation product of lipid peroxides, have been found associated with current smoking status in population-based studies.2021 Similarly, higher levels of thiobarbituric acid reactive substances (TBARS) have been found in smokers compared to nonsmokers.22 New evidence for the association of systemic oxidative stress with pulmonary function comes from population-based study23 conducted in the New York State (n = 2,346). Ochs-Balcom and coworkers23 showed an inverse association of TBARS with percentage of predicted FEV1 and percentage of predicted FVC in men but not in women, suggesting gender differences in the relation of oxidative stress to pulmonary function.

Exposure to oxidant chemicals in smoke is associated with depletion of endogenous levels of antioxidants in the systemic compartment. Numerous studies have reported that smoking results in low antioxidant concentrations in plasma. The total plasma Trolox-equivalent antioxidant capacity (TEAC) was significantly lower in smokers than in nonsmokers.1224 However, no relationship was found between spirometric end points (FEV1 or FEV1/FVC) and plasma levels of TEAC in healthy smokers.24 The third National Health and Nutrition Examination Survey (NHANES) and other studies1725 reported that smokers have significantly lower serum levels of vitamin C, {alpha}-carotene, ß-carotene, ß-cryptoxanthin, melatonin, {alpha}-tocopherol, and lutein/zeaxanthin. However, diet could also influence levels of antioxidants, and independent effects of smoking have only been shown on plasma levels of vitamin C and ß-carotene.252627 In addition, an inverse relationship between cigarette consumption and plasma levels of vitamin C and ß-carotene corrected for habitual dietary intake has been found.2728 Such decreases in plasma antioxidants can disturb the normal oxidative-antioxidative balance in smokers. Remarkably, numerous studies2930 have shown that antioxidant supplements provide at best only a limited protection.

Glutathione (GSH) is a major antioxidant used to eliminate peroxides to nontoxic hydroxyl fatty acids and/or water and to maintain vitamins C and E in their reduced and functional forms. Cigarette smoke contains ROS that oxidize GSH to disulfide form (oxidized glutathione), resulting in decreased plasma GSH levels.31 Similar processes are responsible for an even more extensive oxidation of the cysteine (Cys)/oxidized cysteine (CySS) redox couple and reduced Cys levels showing that smoking has additional effects on sulfur amino acid metabolism. Taking into account that cysteine is the critical molecule for normal GSH synthesis, this observation suggests that evaluation of the Cys/CySS redox couple may be a new sensitive marker of oxidative stress in smokers. In summary, the oxidative burden in the systemic compartment of smokers is mainly characterized by elevated levels of peroxides (isoprostanes and TBARS) and decreased levels of traditional plasma antioxidants (vitamins A and C), whereas GSH-related antioxidants are affected to a lesser extent.

Systemic Inflammation in Smokers

Activation and release of inflammatory cells into the circulation, and an increase in circulating inflammatory mediators such as acute phase proteins and proinflammatory cytokines, characterize the systemic inflammation.

Circulating Inflammatory Cells
The systemic inflammatory response is characterized by the stimulation of the hematopoietic system, specifically the bone marrow resulting in the release of leukocytes and platelets into the circulation. Numerous studies323334 have shown that long-term cigarette smoking increases total WBC counts, mainly due to an increase in polymorphonuclear neutrophil (PMN) counts in the circulation of smokers. A large population-based study35 of 6,902 men and 8,405 women performed in Great Britain revealed that current smoking had a stronger effect on mean total WBC than cumulative exposure as measured by pack-years. However, other authors36 reported a dose-response relationship with pack-years smoked and WBC. This inflammatory response in smokers is characterized not only by an increase in the number of circulating cells but also by phenotypic changes. Indeed, neutrophilia related to chronic smoking was associated with an increase in numbers of circulating band cells, a hallmark of early bone marrow release of PMNs, and an increase in L-selectin expression, a cell adhesion molecule, constitutively highly expressed on maturating PMNs.32 L-selectin could initiate the adherence of PMNs to endothelium and has been shown to be important for the recruitment of PMNs to inflamed tissue.37 In addition, PMNs from smokers have higher levels of myeloperoxidase, an enzyme produced at the early stages of PMN proliferation.3238 Overall, these findings suggest that smoking causes bone marrow stimulation and the release of younger cells from bone marrow. van Eeden and colleagues39 speculated that circulating cytokines like interleukin (IL)-1ß and IL-6 may be responsible for bone marrow stimulation induced by lung inflammation. Indeed, the same authors39 have shown that IL-6 cytokine also potently stimulates the bone marrow to release leukocytes and platelets.

Reports40 have underlined the role of T-lymphocytes as a potentially important factor in the systemic inflammatory process associated with smoking-induced diseases like COPD. Some studies414243 have reported increased total numbers of circulating T-lymphocytes in humans exposed to cigarette smoke. Studies investigating the influence of smoking on different lymphocyte subsets have produced conflicting data. In heavy smokers, a decrease in CD4+ cells (helper T-cells) and increase in CD8+ cells (suppressor T-cells) with subsequent decrease in CD4+/CD8+ ratio have been reported.41 In contrast, Tollerud and colleagues44 found that cigarette smoke was associated with an increase in leukocyte count with a selective increase in CD4+ cells, resulting in significant increase in the CD4+/CD8+ ratio in healthy white subjects. Other studies4546 support these findings. Further analysis has shown that smokers have higher absolute numbers of peripheral blood memory T-cells and naive T-cells as compared with nonsmokers.4346 Analysis of T-cell subpopulations in heavy and light-to-moderate smokers revealed that numbers of memory T-cells were significantly correlated with daily cigarette consumption.42 Overall, the results of these studies suggest that smoking may exert a selective influence on subsets of T-cells. Therefore, taking into account the role of lymphocytes in a number of inflammatory conditions associated with smoking, additional studies would be relevant to better understand the response of circulating lymphocytes to cigarette smoke.

Inflammatory Mediators in Peripheral Blood of Smokers
Activated inflammatory cells produce a great variety of inflammatory mediators in response to cigarette smoke, first of all, acute-phase proteins (APPs) and cytokines. Conditions that commonly lead to substantial changes in the plasma concentrations of APPs and cytokines include infection, trauma, surgery, burns, tissue infarction, various immunologically mediated inflammatory conditions, and cancer. In recent years, these inflammatory mediators have been studied as potential markers of subtle and persistent systemic alterations. Many studies have reported changes in levels of inflammatory mediators not only in the lungs but also in the circulation of healthy smokers. Several studies474849 have reported strong associations between cigarette smoking and different APPs such as C-reactive protein (CRP) and fibrinogen (Table 2 ).


View this table:
[in this window]
[in a new window]

  		Table 2. Baseline Information on Complex Studies of Smoking Effect on Levels of Inflammatory, Endothelial Dysfunction and Hemostatic Markers*

 
For example, the large-scale, population-based NHANES III study revealed a strong independent dose-response relationship between cigarette smoking and elevated levels of CRP and fibrinogen.50 This analysis was based on > 4,187 current smokers, 4,791 former smokers, and 8,375 never-smokers with smoking status based on cotinine levels and was adjusted for different confounders. These findings are in accordance with results of two other studies4751 of APPs in smokers. Data from several prospective studies support the hypothesis that CRP, and fibrinogen levels in particular, are primarily related to lifetime exposure of smoking (pack-years) and not to years since quitting smoking. In the MONICA Augsberg Study49 and the Speedwell Study,52 CRP was still significantly raised 10 years after smoking cessation. Data from the British Regional Heart Study33 indicate that smoking cessation results in a rapid reduction in hemostatic and inflammatory markers, but CRP levels remained significantly raised after 10 to 19 years and did not revert to that of never-smokers until after 20 years; for CRP, the reduction was dependent on the number of cigarettes smoked. A dose-effect relationship between the number of cigarette smoked per day and plasma fibrinogen concentrations have also been reported.5354 Interestingly, the NHANES III study (of 7,685 participants) confirmed that cigarette smoking contributes significantly to low-grade systemic inflammation and, furthermore, shows that reduced lung function by itself is also associated with increased odds of elevated CRP, fibrinogen, and blood leukocytes; but having both risk factors suggests an additive effect contributing to higher levels of systemic inflammation in susceptible individuals.55 Furthermore, a large-scale population-based study56 confirmed that low FVC was associated with higher plasma levels of fibrinogen, {alpha}1-antitrypsin, haptoglobin, ceruloplasmin, and {alpha}1-acid glycoprotein, and with increased incidences of myocardial infarction and cardiovascular death. However, the nature of the observed associations between decreased lung function and APPs induction is still unclear.

The role of other APPs is less extensively investigated. It has been reported that concentrations of {alpha}1-acid glycoprotein, ceruloplasmin, and {alpha}2-macroglobulin are increased in the plasma of smokers as compared to nonsmokers by 39%, 28%, and 12%, respectively.57 Furthermore, the large prospective Malmö Preventive Project study58 with 18-year follow-up revealed that all measured APP levels ({alpha}1-acid glycoprotein, {alpha}1-antitrypsin, haptoglobin, fibrinogen, and ceruloplasmin) increased significantly with increasing cigarette consumption in healthy adult men, independent of other known cardiovascular risk factors.

While these blood changes in smokers may simply be markers of smoking-induced tissue damage, it is also possible that high APP levels may have a direct effect on the promotion of cardiovascular diseases. Increased levels of CRP and fibrinogen have been associated with risk for subsequent cardiovascular events in several large prospective studies.5960 Another study61 showed that CRP might be not only a biomarker of different cardiovascular diseases but may have direct effects on the pathogenesis of atherosclerosis and endothelial dysfunction. For example, CRP stimulates IL-6 and endothelin-1 production and upregulates adhesion molecules, promoting a cascade of events that can lead to clot formation and even promotes atherosclerosis in apolipoprotein E-deficient mice.62 However, the exact role of CRP in development of cardiovascular diseases is still under discussion.63 Some causative speculations are also discussed concerning the role of fibrinogen in atherogenesis. Probably, fibrinogen may promote cardiovascular diseases through effects on blood viscosity, platelet aggregation, and fibrin formation.64 In conclusion, these data clearly indicate that CRP and fibrinogen levels are markedly increased in smokers, possibly contributing to the proinflammatory and proatherogenic effects of chronic smoking exposure.

Raised levels of plasma APPs may partly reflect elevations of inflammatory cytokines such as IL-6 and tumor necrosis factor (TNF)-{alpha}, which are major inductors of APP and, therefore, regulators of systemic inflammatory response. Similarly to APPs, increased levels of proinflammatory cytokines like TNF-{alpha} and IL-6 have been shown to be a risk factor and predictor for myocardial infarction, coronary heart disease, and stroke.6566

Several studies1751 have shown increased levels of TNF-{alpha} and IL-6 in smokers. The population-based MONICA III North Glasgow study67 revealed that mean IL-6 levels were substantially raised in current smokers (by approximately 46% compared to never-smokers), while ex-smokers had similar levels of IL-6 to never-smokers. Furthermore, a significant correlation was found between IL-6 and fibrinogen, and IL-6 and WBC counts, reflecting the major role of IL-6 as inducer of fibrinogen. The Women’s Health Study51 from the United States showed a trend toward increasing IL-6 levels across never, former, and current smoking women. Further, Wirtz and colleagues68 reported a trend for higher baseline TNF-{alpha} levels among healthy smokers. However, a study conducted by Gander and coworkers69 failed to show significant effects of smoking on TNF-{alpha} plasma levels.

Taken as a whole, these data suggest that there are limited data yet on circulating concentrations of IL-6 and TNF-{alpha} in healthy smokers. Taking into account the possible predictive effects of major cytokines for cardiovascular diseases, it would be worth to address large-scale population-based studies to investigate potential relationship of cytokine plasma levels with traditional cardiovascular risk factors including smoking.

Smoking and Markers of Endothelial Dysfunction, Coagulation, and Hemostasis

The biological mechanism linking smoking and atherogenesis, the process leading to cardiovascular diseases, is complex and not fully understood. Besides inflammation, proposed potential mechanisms by which smoking increases the risk of cardiovascular pathology include several other pathways: vascular endothelial dysfunction, systemic hemostatic and coagulation disturbances, and lipid abnormalities. Many of these indexes including fibrinogen (marker of coagulation), fibrin d-dimer (a marker of cross-linked fibrin turnover), and tissue plasminogen activator antigen (t-PA, marker of endothelial dysfunction) have been identified as independent predictors of subsequent cardiovascular events in prospective studies7071 conducted in healthy subjects. In addition, platelet hyperaggregation and activation, plasma viscosity, and plasminogen activator inhibitor (PAI) type I (marker of impaired fibrinolysis) levels have also been associated with cardiovascular morbidity and mortality in prospective studies.7273 The effect of smoking on these variables has also been investigated in several cross-sectional studies, as will be discussed below (Table 2).

Vascular Endothelial Dysfunction
Endothelial dysfunction is mainly caused by diminished production or availability of NO.61 It has been demonstrated that the serum concentration of nitrate and nitrite, metabolic end-products of NO, is significantly decreased in smokers relative to that in nonsmokers.74 In cigarette smokers, low-density lipoprotein (LDL) is more prone to oxidation due to higher level of ROS and reactive nitrogen species.75 Oxidatively modified LDL limits the bioactivity of endothelium-derived NO; and, in turn, the loss of NO bioactivity is associated with increased inflammatory cell entry into the arterial wall.76 Oxidatively modified LDL is taken up by macrophage scavenger receptors, promoting cholesterol ester accumulation and foam cell formation.

Most recently, upregulation of the CD40/CD40L dyad and increased platelet/monocyte aggregation have been proposed as potential contributors to the atherothrombotic consequences of smoking.77 CD40-CD40 ligand couples, members of TNF family, are coexpressed by all of the major cellular players in atherosclerosis. In particular, smokers appeared to have elevated plasma levels of soluble CD40 and increased surface expression of CD40 on monocytes together with increased CD40 ligand on platelets. Furthermore, plasma cotinine concentrations correlated with CD40 and CD40 ligand expression, and with rate of platelet-monocyte aggregations. A recent study suggests that oxidatively modified LDL may play the role of initial trigger for CD40/CD40L expression in human endothelial and smooth-muscle cells.78

Dysfunctional endothelial cells lose their critical physiologic property of nonadherence to circulating immune effector cells (monocytes, macrophages, T-lymphocytes, platelets). Some adhesion molecules are known to be elevated in plasma of smokers. Several groups reported significantly higher levels of soluble intracellular adhesion molecule (ICAM)-1 and P-selectin and E-selectin in current smokers than in nonsmokers among healthy women.5179 A dose-dependent relationship was observed between plasma ICAM-1 concentration and daily cigarette consumption, plasma cotinine level, and exhaled carbon monoxide level.80 Generally, impaired endothelial function caused by cigarette smoking may lead to increased susceptibility of vasculature to atheroma formation and can be considered as an early feature of atherogenesis in humans.81

Hemostatic and Coagulation Markers
There is increasing evidence that blood levels of rheologic variables are associated with subsequent cardiovascular events.70 These indexes include whole-blood viscosity and its main determinants: hematocrit and plasma viscosity, principally composed by plasma fibrinogen and lipoproteins.67 Several studies3367 revealed that current smokers have increased blood viscosity, associated with increased hematocrit or/and plasma viscosity resulting in a procoagulant condition. Increased plasma viscosity may be caused by higher levels of fibrinogen reported in plasma of smokers, as have been discussed before in this review.

Furthermore, elevated levels of markers of fibrinolysis have been reported in healthy smokers. t-PA, the main fibrinolytic activator, converting plasminogen to plasmin is synthesized by endothelial cells. In vivo studies82 have demonstrated major impairment of t-PA release from the vascular endothelium of smokers. The primary inhibitor of fibrinolysis is PAI-I, which inhibits plasminogen activation by binding with t-PA to form the PAI/t-PA complexes. Current smoking is associated with a significant increase in t-PA antigen, which represents mainly the circulating PAI/t-PA complexes and indicates impaired fibrinolytic activity in smokers.3334 Supporting previous findings,3483 plasma PAI-1 antigen and/or activity is significantly higher in smokers than in nonsmokers and is correlated with pack-years smoked.

Plasmin promotes the degradation of fibrin within the thrombus, disintegrating clots, and hence maintains vascular patency. Fibrin d-dimer is a degradation product of cross-linked fibrin that is related to cardiovascular diseases risk.52 As been reported, smoking is positively associated with fibrin d-dimer.3384 The increased d-dimer in smokers probably reflects increased coagulation activation because this antigen is present in several degradation products from the cleavage of cross-linked fibrin by plasmin.85 Taking into account possible adverse effects of abnormal fibrinolysis and excess coagulation on vascular health, further studies are essential to evaluate the impairment of the fibrinolytic system in smokers.

Overall, data presented in this review suggest that smoking is one of the major lifestyle factors influencing levels of a number of novel inflammatory, coagulation, and hemostatic markers associated with common widespread diseases in population-based prospective studies. Systemic oxidative stress followed by low-grade inflammation and endothelial dysfunction caused by chronic smoking exposure could be one of "real-working" mechanisms that explain increased prevalence of common diseases of modern civilization like coronary heart disease, peripheral vascular disease, and COPD in smokers. However, this hypothesis has to be taken cautiously because not all smokers acquire one or more of these diseases. It clearly suggests the existence of other mechanisms influencing common disease development, and, beyond doubt, genetic susceptibility is one of them.86 Different approaches like case-control and whole-genome association studies, linkage analysis of extended pedigrees, and affected sibling pairs are used to dissect genetic component of complex traits. For genetically complex disease like cardiovascular diseases, common disease-common variant hypothesis has been put forward, which assumes that common disease susceptibility or resistance variants are expected to be few at each genetic locus, relatively common in the human population and enriched in the coding and regulatory sequence of genes.87 Despite the small effects of such genes individually, the magnitude of their attributable risk may be large because they are quite frequent in the population, making them of public health significance. However, there is a possibility that many rare variants, each with small contribution, underlie the susceptibility to common human disease.88 Nevertheless, it seems that complete model of complex disease initiation and progression is based on cooperation where these multiple genes are likely to operate through interactions with many environmental factors where smoking is only one but a very important variable.

Conclusion

The possible biological mechanisms responsible for the observed association of smoking with various diseases and global mortality are numerous and, in spite of a many attempts to find causative relationships, are still unclear. It is a great scientific task to unravel exact pathways through which smoking affects human health. Although the effects of smoking on inflammatory markers may persist for many years, a majority of the adverse health effects of smoking are reversible. Therefore, quitting smoking avoids much of the excess health-care risk associated with smoking and allows increasing life expectancy.

Footnotes

Abbreviations: APP = acute-phase protein; CRP = C-reactive protein; Cys = cysteine; CySS = oxidized cysteine; GSH = glutathione; ICAM = intracellular adhesion molecule; IL = interleukin; LDL = low-density lipoprotein; NHANES = National Health and Nutrition Examination Survey; NO = nitric oxide; PAI = plasminogen activator inhibitor; PGF2 = prostaglandin F2; PMN = polymorphonuclear neutrophil; ROS = reactive oxygen species; TBARS = thiobarbituric acid-reactive substances; TEAC = Trolox-equivalent antioxidant capacity; TNF = tumor necrosis factor; t-PA = tissue plasminogen activator

Funding was provided by the European Respiratory Society (fellowship No. 161).

The authors have no conflicts of interest to disclose.

Received for publication September 1, 2006. Accepted for publication October 16, 2006.

References

  1. Edwards, R (2004) The problem of tobacco smoking. BMJ 328,217-219[Free Full Text]
  2. Tobacco control: country profiles. Atlanta, GA: American Cancer Society, 2000
  3. World health report 2002: Reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization, 2002
  4. Crofton, J, Bjartveit, K Smoking as a risk factor for chronic airways disease. Chest 1989;96(3 suppl),307S-312S
  5. Boyle, P Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer 1997;17,1-60[CrossRef][ISI][Medline]
  6. van der Vaart, H, Postma, DS, Timens, W, et al Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 2004;59,713-721[Abstract/Free Full Text]
  7. Pryor, W, Stone, K Oxidants in cigarette smoke radicals, hydrogen peroxides, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 1993;28,12-27
  8. MacNee, W Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2,50-60[Abstract/Free Full Text]
  9. van Antwerpen, VL, Theron, AJ, Richards, GA, et al Vitamin E, pulmonary functions, and phagocyte-mediated oxidative stress in smokers and nonsmokers. Free Radic Biol Med 1995;18,935-941[CrossRef][ISI][Medline]
  10. Ludwig, PW, Hoidal, JR Alterations in leukocyte oxidative metabolism in cigarette smokers. Am Rev Respir Dis 1982;126,977-980[ISI][Medline]
  11. Michaud, SE, Dussault, S, Haddad, P, et al Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis 2006;187,423-432[CrossRef][ISI][Medline]
  12. Petruzzelli, S, Puntoni, R, Mimotti, P, et al Plasma 3-nitrotyrosine in cigarette smokers. Am J Respir Crit Care Med 1997;156,1902-1907[Abstract/Free Full Text]
  13. Takajo, Y, Ikeda, H, Takajo, Y, et al Augmented oxidative stress of platelets in chronic smokers: mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. J Am Coll Cardiol 2001;38,1320-1327[Abstract/Free Full Text]
  14. Pignatelli, B, Li, CQ, Boffetta, P, et al Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 2001;61,778-784[Abstract/Free Full Text]
  15. Morrow, JD, Frei, B, Longmire, AW, et al Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med 1995;332,1198-1203[Abstract/Free Full Text]
  16. Reilly, M, Delanty, S, Lawson, JA, et al Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;94,19-25[Abstract/Free Full Text]
  17. Helmersson, J, Larsson, A, Vessby, B, et al Active smoking and a history of smoking are associated with enhanced prostaglandin F(2{alpha}), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 2005;181,201-207[CrossRef][ISI][Medline]
  18. Gniwotta, C, Morrow, JD, Roberts, LJ, II, et al Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997;17,3236-3241[Abstract/Free Full Text]
  19. Schwedhelm, E, Bartling, A, Lenzen, H, et al Urinary 8-iso-prostaglandin F2{alpha} as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004;109,843-848[Abstract/Free Full Text]
  20. Rumley, AG, Woodward, M, Rumley, A, et al Plasma lipid peroxides: relationships to cardiovascular risk factors and prevalent cardiovascular disease. QJM 2004;97,809-616[Abstract/Free Full Text]
  21. Smith, FB, Lowe, GD, Fowkes, FG, et al Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 1993;102,155-162[CrossRef][ISI][Medline]
  22. Orhan, H, Evelo, CT, Sahin, G Erythrocyte antioxidant defense response against cigarette smoking in humans: the glutathione S-transferase vulnerability. J Biochem Mol Toxicol 2005;19,226-233[CrossRef][ISI][Medline]
  23. Ochs-Balcom, HM, Grant, BJ, Muit, P, et al Oxidative stress and pulmonary function in the general population. Am J Epidemiol 2005;162,1137-1145[Abstract/Free Full Text]
  24. Rahman, I, Swarska, E, Henry, M, et al Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease? Thorax 2000;55,189-193[Abstract/Free Full Text]
  25. Wei, W, Kim, Y, Boudreau, N Association of smoking with serum and dietary levels of antioxidants in adults: NHANES III, 1988–1994. Am J Public Health 2001;91,258-264[Abstract]
  26. Lykkesfeldt, J, Christen, S, Wallock, LM, et al Ascorbate is depleted by smoking and repleted by moderate supplementation: a study in male smokers and nonsmokers with matched dietary antioxidant intakes. Am J Clin Nutr 2000;71,530-536[Abstract/Free Full Text]
  27. Schectman, G, Byrd, JC, Gruchow, HW The influence of smoking on vitamin C status in adults. Am J Public Health 1989;79,158-162[Abstract/Free Full Text]
  28. Marangon, K, Herbeth, B, Lecomte, E, et al Diet, antioxidant status, and smoking habits in French men. Am J Clin Nutr 1998;67,231-239[Abstract]
  29. Fuller, CJ, May, MA, Martin, KJ The effect of vitamin E and vitamin C supplementation on LDL oxidizability and neutrophil respiratory burst in young smokers. J Am Coll Nutr 2000;19,361-369[Abstract/Free Full Text]
  30. Pellegrini, MP, Newby, DE, Johnston, NR, et al Vitamin C has no effect on endothelium-dependent vasomotion and acute endogenous fibrinolysis in healthy smokers. J Cardiovasc Pharmacol 2004;44,117-124[CrossRef][ISI][Medline]
  31. Moriarty, SE, Shah, JH, Lynn, M, et al Oxidation of glutathione and cysteine in human plasma associated with smoking. Free Radic Biol Med 2003;35,1582-1588[CrossRef][ISI][Medline]
  32. van Eeden, SF, Hogg, JC The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000;15,915-921[Abstract]
  33. Wannamethee, SG, Lowe, GD, Shaper, AG, et al Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005;26,1765-1773[Abstract/Free Full Text]
  34. Yarnell, JW, Sweetnam, PM, Runley, A, et al Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol 2000;20,271-279[Abstract/Free Full Text]
  35. Smith, MR, Kinmonth, KL, Luben, RN, et al Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. Atherosclerosis 2003;169,331-337[CrossRef][ISI][Medline]
  36. Yarnell, JW, Sweetnam, PM, Rogers, S, et al Some long term effects of smoking on the haemostatic system: a report from the Caerphilly and Speedwell Collaborative Surveys. J Clin Pathol 1987;40,909-913[Abstract/Free Full Text]
  37. Tedder, TF, Steeber, DA, Chen, A, et al The selectins: vascular adhesion molecules. FASEB J 1995;9,866-873[Abstract]
  38. Dash, S, Sen, S, Behera, D High neutrophil myeloperoxidase activity in smokers [letter]. Blood 1991;77,1619[Free Full Text]
  39. van Eeden, SF, Yeung, A, Quinlam, K, et al Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2,61-67[Abstract/Free Full Text]
  40. Kim, WD, Kim, WS, Koh, Y, et al Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. Chest 2002;122,437-444[CrossRef][Medline]
  41. Miller, LG, Goldstein, G, Murphy, M, et al Reversible alterations in immunoregulatory T cells in smoking: analysis by monoclonal antibodies and flow cytometry. Chest 1982;82,526-529[ISI][Medline]
  42. Tanigawa, T, Araki, S, Nakata, A, et al Increase in memory (CD4+CD29+ and CD4+CD45RO+) T and naive (CD4+CD45RA+) T-cell subpopulations in smokers. Arch Environ Health 1998;53,378-383[ISI][Medline]
  43. Hughes, DA, Haslam, PL, Townsend, PJ, et al Numerical and functional alterations in circulatory lymphocytes in cigarette smokers. Clin Exp Immunol 1985;61,459-466[ISI][Medline]
  44. Tollerud, DJ, Clark, JW, Brown, LM, et al The effects of cigarette smoking on T cell subsets: a population-based survey of healthy Caucasians. Am Rev Respir Dis 1989;139,1446-1451[ISI][Medline]
  45. Mili, F, Flanders, WJ, Boring, JR, et al The associations of race, cigarette smoking, and smoking cessation to measures of the immune system in middle-aged men. Clin Immunol Immunopathol 1991;59,187-200[CrossRef][ISI][Medline]
  46. Schaberg, T, Theilacker, C, Nitschke, OT, et al Lymphocyte subsets in peripheral blood and smoking habits. Lung 1997;175,387-394[CrossRef][ISI][Medline]
  47. Rohde, LE, Hennekens, CH, Ridker, PM Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999;84,1018-1022[CrossRef][ISI][Medline]
  48. Mendall, MA, Strachan, DP, Butland, BK, et al C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21,1584-1590[Abstract/Free Full Text]
  49. Frohlich, M, Sund, M, Frolich, M, et al Independent association of various smoking characteristics with markers of systemic inflammation in men: results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003;24,1365-1372[Abstract/Free Full Text]
  50. Bazzano, LA, He, J, Muntner, P, et al Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003;138,891-897[Abstract/Free Full Text]
  51. Bermudez, EA, Rafai, N, Buring, JE, et al Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 2002;89,1117-1119[CrossRef][ISI][Medline]
  52. Lowe, GD, Yarnell, JW, Rumley, A, et al C-reactive protein, fibrin d-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001;21,603-610[Abstract/Free Full Text]
  53. Kannel, WB, D’Agostino, RB, Belanger, AJ Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987;113,1006-1010[CrossRef][ISI][Medline]
  54. Heinrich, J, Balleisen, L, Schulte, H, et al Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14,54-59[Abstract/Free Full Text]
  55. Gan, WQ, Man, SF, Sin, DD The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005;127,558-564[CrossRef][ISI][Medline]
  56. Engstrom, G, Lind, P, Hedblad, B, et al Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002;106,2555-2560[Abstract/Free Full Text]
  57. Tappia, PS, Troughton, KL, Langley-Evans, SC, et al Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci (Lond) 1995;88,485-489[Medline]
  58. Lind, P, Engstrom, G, Stavenow, L, et al Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol 2004;24,577-582[Abstract/Free Full Text]
  59. Danesh, J, Whincup, P, Walker, M, et al Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321,199-204[Abstract/Free Full Text]
  60. Ridker, PM, Haughie, P Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98,731-733[Abstract/Free Full Text]
  61. Szmitko, PE, Wang, CH, Weisel, RD, et al New markers of inflammation and endothelial cell activation: part I. Circulation 2003;108,1917-1923[Free Full Text]
  62. Paul, A, Ko, KW, Li, L, et al C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109,647-655[Abstract/Free Full Text]
  63. Jialal, I, Devaraj, S, Venugopal, SK C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44,6-11[Abstract/Free Full Text]
  64. Kamath, S, Lip, GY Fibrinogen: biochemistry, epidemiology and determinants. QJM 2003;96,711-729[Free Full Text]
  65. Ridker, PM, Rifai, N, Stampfer, MJ, et al Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101,1767-1772[Abstract/Free Full Text]
  66. Cesari, M, Penninx, BW, Newman, AB, et al Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108,2317-2322[Abstract/Free Full Text]
  67. Woodward, M, Rumley, A, Tunstall-Pedoe, H, et al Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999;104,246-257[CrossRef][ISI][Medline]
  68. Wirtz, PH, von Kanel, R, Kunz-Ebrecht, S, et al Enhanced glucocorticoid sensitivity of cytokine release from circulating leukocytes stimulated with lipopolysaccharide in healthy male smokers. Brain Behav Immun 2004;18,536-543[CrossRef][ISI][Medline]
  69. Gander, ML, Fischer, JE, Maly, FE, et al Effect of the G-308A polymorphism of the tumor necrosis factor (TNF)-{alpha} gene promoter site on plasma levels of TNF-{alpha} and C-reactive protein in smokers: a cross-sectional study. BMC Cardiovasc Disord 2004;4,17[CrossRef][Medline]
  70. Lowe, GD, Lee, AJ, Rumley, A, et al Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997;96,168-173[CrossRef][ISI][Medline]
  71. Koenig, W, Sund, M, Lowel, H, et al Association between plasma viscosity and all-cause mortality: results from the MONICA-Augsburg Cohort Study 1984–92. Br J Haematol 2000;109,453-458[CrossRef][ISI][Medline]
  72. Lowe, GD, Danesh, J, Lewington, S, et al Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2004;25,252-259[Abstract/Free Full Text]
  73. Thogersen, AM, Jansson, JH, Boman, K, et al High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98,2241-2247[Abstract/Free Full Text]
  74. Node, K, Kitakazi, M, Yoshikawa, H, et al Reversible reduction in plasma concentration of nitric oxide induced by cigarette smoking in young adults. Am J Cardiol 1997;79,1538-1541[CrossRef][ISI][Medline]
  75. Yamaguchi, Y, Haginaka, J, Morimoto, S, et al Facilitated nitration and oxidation of LDL in cigarette smokers. Eur J Clin Invest 2005;35,186-193[CrossRef][ISI][Medline]
  76. Stocker, R, Keaney, JF, Jr Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84,1381-1478[Abstract/Free Full Text]
  77. Harding, SA, Sarma, J, Josephs, DH, et al Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 2004;109,1926-1929[Abstract/Free Full Text]
  78. Schonbeck, U, Gerdes, M, Varo, N, et al Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002;106,2888-2893[Abstract/Free Full Text]
  79. Bergmann, S, Seikmeier, R, Mix, C, et al Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir Physiol 1998;114,269-275[CrossRef][ISI][Medline]
  80. Scott, DA, Stapleton, JA, Wilson, JF, et al Dramatic decline in circulating intercellular adhesion molecule-1 concentration on quitting tobacco smoking. Blood Cells Mol Dis 2000;26,255-258[CrossRef][ISI][Medline]
  81. Behrendt, D, Ganz, P Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002;90,40L-48L[CrossRef][ISI][Medline]
  82. Newby, DE, Wright, RA, Labinjoh, C, et al Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999;99,1411-1415[Abstract/Free Full Text]
  83. Eliasson, M, Asplund, K, Evrin, PE, et al Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin: the Northern Sweden MONICA Study. Atherosclerosis 1995;113,41-53[CrossRef][ISI][Medline]
  84. Yarnell, JW, Sweetnam, PM, Rumley, A, et al Lifestyle factors and coagulation activation markers: the Caerphilly Study. Blood Coagul Fibrinol 2001;12,721-728[CrossRef][ISI][Medline]
  85. Lowe, GD, Rumley, A Use of fibrinogen and fibrin d-dimer in prediction of arterial thrombotic events. Thromb Haemost 1999;82,667-672[ISI][Medline]
  86. Cambien, F, Tiret, L Atherosclerosis: from genetic polymorphisms to system genetics. Cardiovasc Toxicol 2005;5,143-152[CrossRef][ISI][Medline]
  87. Collins, FS, Guyer, MS, Charkravarti, A Variations on a theme: cataloging human DNA sequence variation. Science 1997;278,1580-1581[Free Full Text]
  88. Pritchard, JK, Cox, NJ The allelic architecture of human disease genes: common disease-common variant, or not? Hum Mol Genet 2002;11,2417-2423[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Arch Intern MedHome page
P. N. Mitrou, V. Kipnis, A. C. M. Thiebaut, J. Reedy, A. F. Subar, E. Wirfalt, A. Flood, T. Mouw, A. R. Hollenbeck, M. F. Leitzmann, et al.
Mediterranean Dietary Pattern and Prediction of All-Cause Mortality in a US Population: Results From the NIH-AARP Diet and Health Study
Arch Intern Med, December 10, 2007; 167(22): 2461 - 2468.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yanbaeva, D. G.
Right arrow Articles by Wouters, E. F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanbaeva, D. G.
Right arrow Articles by Wouters, E. F. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS